Granted Patent B2

US 12,319,669 · App. 18/477,050 · Granted Jun 3, 2025

Inventors: Gary Erik Aspnes (Biberach an der Riss, DE); Scott W. Bagley (Voluntown, CT); John M. Curto (Mystic, CT); Matthew S. Dowling (Old Lyme, CT); David Edmonds (Basel, CH); Mark E. Flanagan (Gales Ferry, CT); Kentaro Futatsugi (Sharon, MA); David A. Griffith (Sudbury, MA); Kim Huard (Berkeley, CA); Gajendra Ingle (New Haven, CT); Wenhua Jiao (Salem, CT); Chris Limberakis (Pawcatuck, CT); Alan M. Mathiowetz (Waltham, MA); David W. Piotrowski (Waterford, CT); Roger B. Ruggeri (Waterford, CT)

Assignee: Pfizer Inc.

C07D401/14A61K31/4545A61K31/496A61P1/00A61P1/16A61P3/00A61P3/04A61P3/10A61P9/10A61P13/12A61P15/00A61P15/10A61P17/06A61P19/02A61P19/06A61P25/02A61P25/16A61P25/18A61P25/28A61P25/30A61P43/00C07D405/14C07D413/14C07D471/04C07D487/04

Abstract

Claims (21)

1. A method for treating a disease or disorder in a human comprising administering to the human a compound that is 2-[(4-{6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-{[(2S)-oxetan-2-yl]methyl}-1H-benzimidazole-6-carboxylic acid or 2-[(4-{6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-{[(2R)-oxetan-2-yl]methyl}-1H-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is selected from the group consisting of Type 1 diabetes (T1D), Type 2 diabetes mellitus (T2DM), pre-diabetes, idiopathic T1D, latent autoimmune diabetes in adults (LADA), early-onset T2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, a kidney disease, and diabetic retinopathy.

2. The method of claim 1 wherein the disease or disorder is T1D or idiopathic T1D.

3. The method of claim 1 wherein the disease or disorder is selected from the group consisting of T2DM, pre-diabetes, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, diabetic neuropathy, diabetic nephropathy, and diabetic retinopathy.

4. The method of claim 1 wherein the disease or disorder is T2DM.

5. The method of claim 1 wherein the disease or disorder is selected from the group consisting of hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, and a kidney disease.

6. A method for treating a disease or disorder in a human comprising administering to the human a compound that is 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, wherein disease or disorder is selected from the group consisting of T1D, T2DM, pre-diabetes, idiopathic T1D, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, and diabetic retinopathy.

7. The method of claim 6 wherein the compound is 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

8. The method of claim 6 wherein the compound is a pharmaceutically acceptable salt of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

9. The method of claim 6 wherein the compound is 2-amino-2-(hydroxymethyl)propane-1,3-diol salt (tris salt) of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

10. The method of claim 6 wherein the disease or disorder is T1D or idiopathic T1D.

11. The method of claim 6 wherein the disease or disorder is selected from the group consisting of T2DM, pre-diabetes, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, diabetic neuropathy, diabetic nephropathy, and diabetic retinopathy.

12. The method of claim 6 wherein the disease or disorder is T2DM.

13. The method of claim 6 wherein the disease or disorder is selected from the group consisting of hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, and a kidney disease.

14. The method of claim 8 wherein the disease or disorder is T1D or idiopathic T1D.

15. The method of claim 8 wherein the disease or disorder is selected from the group consisting of T2DM, pre-diabetes, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, diabetic neuropathy, diabetic nephropathy, and diabetic retinopathy.

16. The method of claim 8 wherein the disease or disorder is T2DM.

17. The method of claim 8 wherein the disease or disorder is selected from the group consisting of hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, and a kidney disease.

18. The method of claim 9 wherein the disease or disorder is T1D or idiopathic T1D.

19. The method of claim 9 wherein the disease or disorder is selected from the group consisting of T2DM, pre-diabetes, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, diabetic neuropathy, diabetic nephropathy, and diabetic retinopathy.

20. The method of claim 9 wherein the disease or disorder is T2DM.

21. The method of claim 9 wherein the disease or disorder is selected from the group consisting of hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, and a kidney disease.

Continuity (7)

References Cited (11)